Previously recorded as Isis Pharmaceuticals, Inc. (to 2015)
351 patents currently held
32 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
82
Ending by 2030
Dec 2026
Next term end
200
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2028 · High confidence
Also notable
Ends Apr 2028 · Low confidence
Also notable
Ends no later than May 2034 · Medium confidence
Also notable
Ends Jan 2027 · High confidence
Also notable
Ends Jan 2027 · High confidence
Also notable
Ends Jul 2031 · Medium confidence
Also notable
Ends Apr 2033 · High confidence
Also notable
Ends Nov 2027 · High confidence
Oligomeric Compounds Comprising 4'-Thionucleosides for Use in Gene Modulation
US 7,875,733
Cited by 346 later US patents, top 1% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Short Antisense Compounds with Gapmer Configuration
US 9,045,754
Cited by 119 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
Conjugated Antisense Compounds and Their Use
US 9,127,276
Cited by 146 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
6-Modified Bicyclic Nucleic Acid Analogs
US 7,399,845
The most cited patent in this portfolio, cited by 482 later US patents, top 1% of utility patents granted in 2008 in our data. Protection runs to 2027.
Compositions and Their Uses Directed to Huntingtin
US 7,951,934
Cited by 116 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression
US 9,765,338
Cited by 68 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof
US 9,914,922
Cited by 111 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Methods for Treating Hypercholesterolemia
US 8,084,437
Cited by 60 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Methods for Modulating FMR1 Expression (US 11,661,601) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Dec 23, 2026The maintenance fee for Modulation of Transthyretin Expression (US 9,061,044) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 3 fees due Jan 2 to 30, 2027 · next Jan 2
- 8 fees due Feb 1 to 22, 2027 · next Feb 1
- 9 fees due Mar 3 to 22, 2027 · next Mar 3
- 9 fees due Apr 1 to 22, 2027 · next Apr 1
- 9 fees due May 3 to 24, 2027 · next May 3
- 9 fees due Jun 3 to 30, 2027 · next Jun 3
- 5 fees due Jul 2 to 26, 2027 · next Jul 2
- 2 fees due Aug 11 to 25, 2027 · next Aug 11
- 7 fees due Sep 1 to 22, 2027 · next Sep 1
- 6 fees due Oct 14 to 26, 2027 · next Oct 14
- 2 fees due Nov 14 to 17, 2027 · next Nov 14
Recent changes
- Nov 18Assignment recorded on 1 record: Rigo, Frank and 4 others to Ionis Pharmaceuticals, Inc. Recorded Nov 18, 2026, executed Jun 22, 2021. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76797, frame 390.
- Nov 18Assignment recorded on 9 records: Ionis Pharmaceuticals, Inc. to Biogen Ma Inc. Recorded Nov 18, 2026, executed Sep 17, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76797, frame 422.
- 7 of the patents on this record were granted since Aug 23, 2026
- 2 terms have ended since Aug 23, 2026
- Nov 20 US 8,268,980 5'-Modified Bicyclic Nucleic Acid Analogs · term ended
- Aug 29 US 9,157,081 Chimeric Oligomeric Compounds for Modulation of Splicing · term ended
What they patent
The largest of its 200 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,114,856 | Antibacterial 4,5-Substituted Aminoglycoside Analogs Having Multiple Substituents In force · Medium confidence | In force | Medium confidence | |
| US 8,569,264 | Antibacterial 4,5-Substituted Aminoglycoside Analogs Having Multiple Substituents In force · Low confidence | In force | Low confidence | |
| US 7,951,934 | Compositions and Their Uses Directed to Huntingtin In force · High confidence | In force | High confidence | |
| US 8,415,465 | Compositions and Their Uses Directed to Huntingtin In force · High confidence | In force | High confidence | |
| US 8,952,145 | Compositions and Their Uses Directed to Huntingtin In force · High confidence | In force | High confidence | |
| US 9,057,066 | Compositions and Their Uses Directed to Huntingtin In force · Medium confidence | In force | Medium confidence | |
| US 9,353,372 | Compositions and Their Uses Directed to Huntingtin In force · High confidence | In force | High confidence | |
| US 9,920,321 | Compositions and Their Uses Directed to Huntingtin In force · High confidence | In force | High confidence | |
| US 10,655,129 | Compositions and Their Uses Directed to Huntingtin In force · High confidence | In force | High confidence | |
| US 10,738,307 | Compositions and Their Uses Directed to Huntingtin held by CHDI Foundation, Inc. In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 351: 32 patents in force now held by others · 196 patents ended · 141 applications pending · 234 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.